FDA Inspection 1305006 — Labcorp Development (Asia) Pte. Ltd
The FDA completed an inspection of Labcorp Development (Asia) Pte. Ltd on January 30, 2026 in Singapore. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- January 30, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Singapore (Singapore)
Additional Details
Bioanalytical BA/BE